Inhibition of ceramide-redox signaling pathway blocks glomerular injury in hyperhomocysteinemic rats

Kidney International

Volumn 70, Issue 1, 2006, Pages 88-96

  Yi, F ^a   Zhang, A Y ^a   Li, N ^b   Muh, R W ^b   Fillet, M ^c   Renert, A F ^c   Li, P L ^a,b,d  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF LIÈGE   (Belgium)

^d VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

End stage renal disease; Homocysteine; Kidney; Oxidative stress; Sphingolipid

Indexed keywords

APOCYNIN; CERAMIDE; GUANOSINE TRIPHOSPHATASE; HOMOCYSTEINE; MATRIX METALLOPROTEINASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SPHINGOLIPID; THERMOZYMOCIDIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

AMINO ACID METABOLISM; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; EXTRACELLULAR MATRIX; GLOMERULAR DYSFUNCTION; GLOMERULOSCLEROSIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HYPERHOMOCYSTEINEMIA; KIDNEY FAILURE; KIDNEY INJURY; MESANGIUM CELL; NONHUMAN; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT; URINARY EXCRETION;

ACETOPHENONES; ANIMALS; CERAMIDES; ENZYME ACTIVATION; ENZYME INHIBITORS; EXTRACELLULAR MATRIX; FATTY ACIDS, MONOUNSATURATED; HOMOCYSTEINE; HYPERHOMOCYSTEINEMIA; KIDNEY CORTEX; KIDNEY DISEASES; KIDNEY GLOMERULUS; MATRIX METALLOPROTEINASE 1; NADPH OXIDASE; OXIDATION-REDUCTION; RAC GTP-BINDING PROTEINS; RATS; RATS, SPRAGUE-DAWLEY; RNA, MESSENGER; SIGNAL TRANSDUCTION; TISSUE INHIBITOR OF METALLOPROTEINASE-1;

EID: 33745711919     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/sj.ki.5001517     Document Type: Article

References (42)

1. Bostom AG, Lathrop L. Hyperhomocysteinemia in end-stage renal disease: prevalence, etiology, and potential relationship to arteriosclerotic outcomes. Kidney Int 1997; 52: 10-20.
2. Dennis VW, Nurko S, Robinson K. Hyperhomocysteinemia: detection, risk assessment, and treatment. Curr Opin Nephrol Hypertens 1997; 6: 483-488.
3. Dennis VW, Robinson K. Homocysteinemia and vascular disease in end-stage renal in patients with chronic renal failure. Kidney Int 1997; 52: 495-502.
4. Perna AF, Ingrosso D, Castaldo P et al. Homocysteine, a new crucial element in the pathogenesis of uremic cardiovascular complications. Miner Electrolyte Metab 1999; 25: 95-99.
5. Bostom AG, Shemin D, Lapane KL et al. Hyperhomocystinemia and traditional cardiovascular disease risk factors in end-stage renal disease patients on dialysis: a case-control study. Atherosclerosis 1995; 114: 93-103.
6. Ducloux D, Motte G, Challier B et al. Serum total homocysteine and cardiovascular disease occurrence in chronic, stable renal transplant recipients: a prospective study. J Am Soc Nephrol 2000; 11: 134-137.
7. Li N, Chen YF, Zou AP. Implications of hyperhomocysteinemia in glomerular sclerosis in hypertension. Hypertension 2002; 39: 443-448.
8. McCully KS. The Homocysteine Revolution: Medicine for the New Millennium. Keats Publishing: New Canaan, CT, 1997.
9. McCully KS. Chemical pathology of homocysteine. I atherogenesis. II Carcinogenesis and homocysteine thiolacton metabolism. III Cellular function and aging. Ann Clin Lab Sci 1993; 23: 477-493.
10. McCully KS. Atherosclerosis, serum cholesterol and the homocysteine theory: a study of 194 consecutive autopsies. Am J Med Sci 1990; 299: 217-221.
11. De Groote MA, Testerman T, Xu Y et al. Homocysteine antagonism of nitric oxide-related cytostasis in Salmonella typhimurium. Science 1996; 272: 414-417.
12. Harker LA, Ross R, Slichter SJ, Scott CR. Homocystine-induced arteriosclerosis. The role of endothelial cell injury and platelet response in its genesis. J Clin Invest 1976; 58: 731-741.
13. Kanani PM, Sinkey CA, Browning RL et al. Role of oxidant stress in endothelial dysfunction produced by experimental hyperhomocyst(e) inemia in humans. Circulation 1999; 100: 1161-1168.
14. Yang ZZ, Zou AP. Homocysteine enhances TIMP-1 expression and cell proliferation associated with NADH oxidase in rat mesangial cells. Kidney Int 2003; 63: 1012-1020.
15. Yi F, Zhang AY, Janscha J et al. Homocysteine activate NADH/NADPH oxidase through ceramide-stimulated rac activity in rat mesangial cells. Kidney Int 2004; 66: 1977-1987.
16. Yin T, Sandhu G, Wolfgang CD et al. Tissue-specific pattern of stress kinase activation in ischemic/reperfused heart and kidney. J Biol Chem 1997; 272: 19943-19950.
17. Kaushal GP, Singh AB, Shah SV. Identification of caspase (ICE-like proteases) gene family in rat kidney and altered expression in ischemia/reperfusion injury. Am J Physiol 1998; 274: F587-F595.
18. Ueda N, Kaushal GP, Shah SV. Apoptotic mechanisms in acute renal failure. Am J Med 2000; 108: 403-415.
19. Zhang DX, Zou AP, Li PL. Ceramide-induced activation of NADPH oxidase and endothelial dysfunction in small coronary arteries. Am J Physiol Heart Circ Physiol 2003; 284: H605-H612.
20. Duthie SJ, Grant G, Narayanan S. Increased uracil misincorporation in lymphocytes from folate-deficient rats. Br J Cancer 2000; 83: 1532-1537.
21. Miller JW, Nadeau MR, Smith J et al. Folate-deficiency-induced homocysteinaemia in rats: disruption of S-adenosylmethionine's co-ordinate regulation of homocysteine metabolism. Biochem J 1994; 298(Part 2): 415-419.
22. Bonaventura D, Tirapelli CR, Haddad R et al. Chronic methionine load-induced hyperhomocysteinemia enhances rat carotid responsiveness for angiotensin II. Pharmacology 2004; 70: 91-99.
23. Dbaibo GS, El-Assaad W, Krikorian A et al. Ceramide generation by two distinct pathways in tumor necrosis factor alpha-induced cell death. FEBS Lett 2001; 503: 7-12.
24. Tummalapalli CM, Tyagi SC. Responses of vascular smooth muscle cell to extracellular matrix degradation. J Cell Biochem 1999; 75: 515-527.
25. Wallner EI, Yang Q, Peterson DR et al. Relevance of extracellular matrix, its receptors, and cell adhesion molecules in mammalian nephrogenesis. Am J Physiol Renal Physiol 1998; 275: F467-F477.
26. Schaefer L, Han X, August C et al. Differential regulation of glomerular gelatinase B (MMP-9) and tissue inhibitor of metalloproteinase-1 (TIMP-1) in obese Zucker rats. Diabetologia 1997; 40: 1035-1043.
27. Torres L, Garcia-Trevijiano ER, Rodriguez JA et al. Induction of TIMP-1 expression in rat hepatic stellate cells and hepatocytes: a new role for homocysteine in liver fibrosis. Biochim Biophys Acta 1999; 1455: 12-22.
28. Hubchak SC, Runyan CE, Kreisberg JI, Schnaper HW. Cytoskeletal rearrangement and signal transduction in TGF-beta1-stimulated mesangial cell collagen accumulation. J Am Soc Nephrol 2003; 14: 1969-1980.
29. Williams KJ, Tabas I. The response-to-retention hypothesis of early atherogenesis. Arterioscler Thromb Vasc Biol 1995; 15: 551-561.
30. Coroneos E, Martinez M, McKenna S, Kester M. Differential regulation of sphingomyelinase and ceramidase activities by growth factors and cytokines. J Biol Chem 1995; 270: 23305-23309.
31. Hojjati MR, Li Z, Zhou H et al. Effect of myriocin on plasma sphingolipid metabolism and atherosclerosis in apoE-deficient mice. J Biol Chem 2005; 280: 10284-10289.
32. Park TS, Panek RL, Mueller SB et al. Inhibition of sphingomyelin synthesis reduces atherogenesis in apolipoprotein E-knockout mice. Circulation 2005; 110: 34665-34671.
33. Landmesser S, Dikalov SR, Price L et al. Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitric oxide synthase in hypertension. J Clin Invest 2003; 111: 1201-1209.
34. Cai H, Griendling KK, Harrison DG. The vascular NAD(P)H oxidases as therapeutic targets in cardiovascular diseases. Trends Pharmacol Sci 2003; 24: 471-478.
35. Griendling KK, Sorescu D, Lassegue B, Ushio-Fukai M. Modulation of protein kinase activity and gene expression by reactive oxygen species and their role in vascular physiology and pathophysiology. Arteriosder Thromb Vasc Biol 2000; 20: 2175-2183.
36. Takeya RN, Ueno K, Kami M et al. Novel human homologues of p47phox and p67phox participate in activation of superoxide-producing NADPH oxidases. J Biol Chem 2003; 278: 25234-25246.
37. Brandes RP, Kreuzer J. Vascular NADPH oxidases: molecular mechanisms of activation. Cardiovasc Res 2005; 65: 16-27.
38. Geiszt M, Kopp JB, Varnai P, Leto TL. Identification of renox, an NAD(P)H oxidase in kidney. Proc Natl Acad Sci USA 2000; 97: 8010-8014.
39. Bokoch GM, Diebold BA. Current molecular models for NADPH oxidase regulation by Rac GTPase. Blood 2002; 100: 2692-2696.
40. Abo A, Pick E, Hall A et al. Activation of the NADPH oxidase involves the small GTP-binding protein p21rac1. Nature 1991; 353: 668-670.
41. Chen YF, Li PL, Zou AP. Effect of hyperhomocysteinemia on plasma or tissue adenosine levels and renal function. Circulation 2002; 106: 1275-1281.
42. Fillet M, Van Heugen JC, Servais AC et al. Separation, identification and quantitation of ceramides in human cancer cells by liquid chromatography- electrospray ionisation tandem mass spectrometry. J Chromatogr A 2002; 949: 225-233.